tbuckley/cabot-search huggingface dataset:
A prospective randomized phase II trial evaluating maintenance GM-CSF in an intermittent chemotherapy (chemo) regimen for metastatic castration-resistant prostate cancer (mCRPC): A DoD prostate cancer clinical trials consortium trial.
Authors: Eric Jay Small, Vivian K. Weinberg, Charles J. Ryan, Celestia S. Higano, Amy Mimi Lin, Yvonne Maruca, Joshi J. Alumkal, Evan Y. Yu, Jonathan E. Rosenberg, Tomasz M. Beer
Journal: Journal of Clinical Oncology (2012)

35 Background: The optimal number of cycles of docetaxel for patients (pts) with mCRPC is not known, and in practice, treatment breaks are common. The current study was designed to test the safety and efficacy of utilizing 6 cycles of standard docetaxel with chemo free intervals in patients who achieve and maintain a response to docetaxel. Methods: Pts with mCRPC, no prior chemo, and KPS &gt; 60% were eligible. Pts were treated with “induction” docetaxel 75 mg/m2 q 3 weeks, and prednisone 5 mg po bid. PSAWG1 criteria were used to define response and progression. After 6 cycles, responding pts stopped chemo and were randomized to observation (Obs) or to GM-CSF, 250 mcg/m2 daily for 14 days out of every 28-day cycle. Pts were followed with monthly PSA and imaging every 2 cycles until progression, at which point docetaxel was reinitiated for another 6 cycles, followed by the same “off chemo” regimen. The primary endpoint was the time to progression while on chemo (time to chemo resistance). Results: 114 pts have been enrolled: 3 are undergoing induction, and 111 are therefore evaluable. Of these pts, 82 completed induction, (10 did not due to PD, 9 due to adverse events (AE), 10 due to pt or MD choice). Of 111 evaluable pts, 48 (43%) had a response to chemo and were eligible for randomization. 22 were randomized to Obs and 26 to GM-CSF. Of 48 randomized pts, 25 restarted chemo, all for PSA PD. (23 pts did not re-start chemo because of AE, other therapy being started, or pt choice; 1 pt is still on GM-CSF.) 6/25 (24%) pts experienced a response to the 2nd series of chemo, and 1/6 (17%) to the 3rd. The time to chemo re-initiation (n=25) was 3.1 mos in Obs pts and 4.2 mos in GM-CSF pts. Conclusions: 43% of patients met criteria for undergoing intermittent chemo. The response proportion to the 1st, 2nd, and 3rd series of docetaxel was 43%, 24% and 17%, respectively. GM-CSF may modestly delay the time to chemo re-initiation, but the sample size is small and insufficient to assess the impact of GM-CSF on time to chemo resistance.
Overexpression and Preferential Nuclear Translocation of the Transcription Factor Yin Yang 1 (YY1) in Human Bone Marrow-Derived Multiple Myeloma.
Authors: Sara Huerta-Yepez, Stravoula Baritaki, Angeles Hernandez-Cuecto, Yu-Mei Anguino-Hernandez, Mehran Neshat, Haiming Chen, Richard A. Campbell, Melinda S. Gordon, James R. Berenson, Benjamin Bonavida
Journal: Blood (2005)
Immediate Allogeneic Hematopoietic Cell Transplantation (HCT) in Acute Myeloid Leukemia (AML) Arising From Myelodysplastic Syndrome (MDS)
Authors: Sung-Doo Kim, Yunsuk Choi, Young-Hun Park, Jae Seok Lee, Dae-Young Kim, Jung-Hee Lee, Kyoo-Hyung Lee, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ah Rang Jung, Je-Hwan Lee
Journal: Blood (2011)
Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines,
Authors: Cory Mavis, Sarah Frys, Juan Gu, John Gibbs, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2011)
Maternal Fish Consumption and Atopic Manifestations in Infants: The Importance of Amount and Type of Fish
Authors: Lalita Tearprasert, Pantipa Chatchatee, Yong Poovorawan, Nasamon Wanlapakorn, Pasit Kanasirichainon, Leuridan Elke, Pierre Van Damme, Surasith Chaithongwongwatthana, Pathareeyawan Srimuan, Sirinuch Chomtho, Jarungjit Ngamphaiboon, Narissara Suratannon
Journal: Journal of Allergy and Clinical Immunology (2017)
Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021
Authors: W. Tap, Z. Papai, B. van Tine, S. Attia, K. Ganjoo, R.L. Jones, S. Schuetze, D. Reed, S.P. Chawla, R. Riedel, A. Krarup-Hansen, A. Italiano, P. Hohenberger, G. Grignani, L. Cranmer, T. Alcindor, A. Lopez-Pousa, T. Pearce, S. Kroll, P. Schoffski
Journal: Annals of Oncology (2016)
Immunogenicity and Safety of Post-Exposure Rabies Vaccination in Children with Primary Immunodeficiency Disorders
Authors: Kanlada Wongworapat, Suvanee Charoenlap, Pantipa Chatchatee, Terapong Tantawichien, Nattiya Hirankarn, Pimpayao Sodsai, Piyada Udomchaisakul, Pakamazt Khawplod, Jarungjit Ngamphaiboon, Narissara Suratannon
Journal: Journal of Allergy and Clinical Immunology (2017)
Relevance of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) On Non-Relapse Related Mortality (NRM) in Patients with Acute Lymphoblastic Leukemia (ALL) Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Complete Remission: Results From the GMALL Study Group.
Authors: Matthias Stelljes, Mareike David, Renate Arnold, Dietrich W Beelen, Wolfgang A Bethge, Martin Bornhäuser, Jolanta Dengler, Juergen Finke, Hans J Kolb, Karin Kolbe, Nicolaus Kröger, Dietger Niederwieser, Wolf Rösler, Rainer Schwerdtfeger, Joachim Kienast, Nicola Goekbuget, Dieter Hoelzer
Journal: Blood (2009)
AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells.
Authors: Shamim Lotfi, Aarthi Jayanthan, Victor A. Lewis, Greg Guilcher, Matthew S Squires, Todd Cooper, Aru Narendran
Journal: Blood (2009)
Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia
Authors: Hui Fen Zhao, Allistair Abraham, Yoon-Sang Kim, Yong-Dong Wang, Tamara Pestina, Jun Zhan, Keith Humphries, Arthur W. Nienhuis, Derek A. Persons
Journal: Molecular Therapy (2017)

Recently, an engineered Homeobox-nucleoporin fusion gene, NUP98-HOXA10HD or NA10HD, was reported to expand and maintain murine hematopoietic stem cells (HSCs). We postulated that NA10HD would increase the number of human γ-globin-expressing cells to therapeutic levels. We developed a double gene lentiviral vector encoding both human γ-globin and NA10HD, which was used to transduce human peripheral blood CD34+ cells and increased engraftment 2- to 2.5-fold at 15 weeks post-transplantation in immunodeficient mice. In β-thalassemic mice transplanted with β-thalassemic HSCs transduced with the γ-globin/NA10HD vector, the number of fetal hemoglobin (HbF)-expressing cells was significantly increased after 3 months, leading to resolution of the anemia. Furthermore, the increases in HbF were maintained at 6 months and persisted after secondary transplantation. In addition, NA10HD enrichment of transduced HSCs led to HbF increases without affecting homeostasis of the white blood cell lineages. Our results suggest that NA10HD increases the number of γ-globin-transduced HSCs that engraft, leading to an elevated number of fetal hemoglobin-containing red cells. These effects of NA10HD provide an improved platform for testing of the therapeutic efficacy of novel globin vectors and provide further impetus to develop safe and effective methods for selective expansion of genetically modified cells.
In Silico modelling of Sensitivity to Novel Tyrosine Kinase Inhibitors of Highly Resistant Single and Polymutant BCR-ABL1.
Authors: Sabrina Pricl, Don L Gibbons, Paola Posocco, Erik Laurini, Maurizio Fermaglia, Hagop M. Kantarjian, Moshe Talpaz, Jorge Cortes, Nicholas Donato, Alfonso Quintás-Cardama
Journal: Blood (2010)
Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials
Authors: C. Mazaud, L. Fardet
Journal: British Journal of Dermatology (2017)

Low-dose (i.e. ≤ 30 mg per week) methotrexate is widely prescribed by dermatologists. However, there is limited evidence-based information regarding the relative risk of and determinants for adverse events associated with this treatment. The aims of this review were to assess the relative risk of and the determinants for adverse events associated with low-dose methotrexate exposure. A systematic review was undertaken using the MEDLINE, Embase and CENTRAL databases. Randomized controlled trials comparing low-dose methotrexate with placebo were eligible. Random effect meta-analyses were conducted to assess the risk ratios (RRs) of adverse events associated with methotrexate exposure. Subgroup analyses and random effect meta-regressions were performed to examine the determinants of adverse events. In total, 68 trials (6938 participants) were included. Compared with placebo, low-dose methotrexate slightly increased the risk of adverse events (mean number per individual: 1·78 ± 2·00 in the methotrexate group, 1·53 ± 1·89 in the placebo group; P < 0·001), including nausea/vomiting, elevated transaminase levels, mucosal ulcerations, leucopenia, thrombopenia and infectious events, but not the risk of serious adverse events or death. Low-dose methotrexate also increased the number of withdrawals from studies because of adverse events [RR 1·32 (1·13-1·53)]. The concomitant prescription of folic/folinic acid was associated with a significant lower risk of any adverse events, and methotrexate prescribed orally was associated with a higher risk of abdominal pain than when prescribed subcutaneously or by intramuscular injection. On the other hand, the risk of adverse events did not increase with the weekly dose or with duration of exposure. Similar studies comparing methotrexate with other systemic/biological treatments are needed.
Definition of Commonly Deleted Regions and Identification of Candidate Genes of Chromosome 20 in Myeloid Malignancies Using Genome-Wide Single Nucleotide Polymorphism (SNP) Array.
Authors: Jungwon Huh, Ramon V. Tiu, Ying Jiang, Lukasz P Gondek, Christine O’Keefe, Karl S. Theil, Jaroslaw P Maciejewski
Journal: Blood (2008)
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (<scp>RARS</scp>‐<scp>T</scp>): 2017 update on diagnosis, risk‐stratification, and management
Authors: Mrinal M. Patnaik, Ayalew Tefferi
Journal: American Journal of Hematology (2017)

Abstract Disease Overview Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS‐RS) and RARS with thrombocytosis (RARS‐T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T). Diagnosis MDS‐RS is a lower risk MDS, with single or multilineage dysplasia (SLD/MLD), &lt;5% bone marrow (BM) blasts and ≥15% BM RS (≥5% in the presence of SF3B1 mutations). MDS/MPN‐RS‐T, now a formal entity in the MDS/MPN overlap syndromes, has diagnostic features of MDS‐RS‐SLD, along with a platelet count ≥ 450 × 10(9)/L and large atypical megakaryocytes (similar to BCR‐ABL1 negative MPN). Mutations and Karyotype Mutations in SF3B1 are seen in ≥80% of patients with MDS‐RS‐SLD and MDS/MPN‐RS‐T, and strongly correlate with the presence of BM RS; MDS/MPN‐RS‐T patients also demonstrate JAK2 V617F, ASXL1, DNMT3A , SETBP1 , and TET2 mutations; with ASXL1/SETBP1 mutations adversely impacting survival. Cytogenetic abnormalities are uncommon in both diseases. Risk stratification Most patients with MDS‐RS‐SLD are stratified into lower risk groups by the revised‐International Prognostic Scoring System (R‐IPSS). Disease outcome in MDS/MPN‐RS‐T is better than that of MDS‐RS‐SLD, but worse than that of essential thrombocythemia. Both diseases have a low risk of leukemic Treatment Anemia and iron overload are complications seen in both and are managed similar to lower risk MDS and MPN. Aspirin therapy is reasonable in MDS/MPN‐RS‐T, especially in the presence of JAK2 V617F, but the value of platelet‐lowering drugs is uncertain.
Nitrogen Dioxide Exposure in School Classrooms Is Associated with Airflow Obstruction in Students with Asthma
Authors: Jonathan M. Gaffin, Marissa Hauptman, Peggy Lai, Carter R. Petty, Jack M. Wolfson, Choong-Min Kang, William J. Sheehan, Sachin N. Baxi, Lisa M. Bartnikas, Perdita Permaul, Diane R. Gold, Brent Coull, Petros Koutrakis, Wanda Phipatanakul
Journal: Journal of Allergy and Clinical Immunology (2017)
Thromboprophylaxis after Knee Arthroscopy
Authors: Rebecca E. Berger, Menaka Pai, Anita Rajasekhar
Journal: New England Journal of Medicine (2017)

This interactive feature on thromboprophylaxis after knee arthroscopy offers a case vignette accompanied by essays that support either recommending or not recommending thromboprophylaxis. Vote and comment at NEJM.org.
Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study
Authors: Michael Khodadoust, Alain H. Rook, Pierluigi Porcu, Francine M. Foss, Alison J. Moskowitz, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Richard Shine, Steven P Fling, Shufeng Li, Ziba Rabhar, Jinah Kim, Yi Yang, Jennifer Yearley, Elliot Keith Chartash, Steven M. Townson, Priyanka B Subrahmanyam, Holden Maecker, Ash A. Alizadeh, Julia Dai, Steven M Horwitz, Elad Sharon, Holbrook Kohrt, Martin A Cheever, Youn Kim
Journal: Blood (2016)
Long-Term Follow-up Analysis of HD2000 Trial Comparing ABVD Versus BEACOPP Versus Copp/EBV/CAD in Patients with Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study from the Fondazione Italiana Linfomi
Authors: Francesco Merli, Stefano Luminari, Caterina Mammi, Nicola Cascavilla, Alessia Bari, Caterina Stelitano, Renato Scalone, Luca Baldini, Francesco Angrilli, Giuseppe Polimeno, Paolo G Gobbi, Giulia Cervetti, Fiorella Ilariucci, Alessia Ruffini, Luigi Marcheselli, Massimo Federico
Journal: Blood (2014)
Lipid Abnormalities Associated with Skin Lesions in Atopic Dermatitis
Authors: Evgeny Berdyshev, Elena Goleva, Irina Bronova, Cydney Rios, Nathan Dyjack, Agata Wesolowska-Andersen, Clifton F. Hall, Brittany N. Richers, Patricia A. Taylor, Caroline Bronchick, A. Seibold, Donald Y.M. Leung
Journal: Journal of Allergy and Clinical Immunology (2017)
Clinical characteristics and response to attack treatment with Berinert® of drug induced angioedema in the French Cohort COBRA.
Authors: Laurence Bouillet, Isabelle Boccon-Gibod, Anne Pagnier, Anne Gompel, Bernard Floccard, Ludovic Martin, Claire Blanchard-Delaunay, David Launay, Olivier Fain, Alain Sobel
Journal: Journal of Allergy and Clinical Immunology (2017)
Acute Myeloid Leukemia Stem Cells Escape Innate Immune Surveillance by Macrophages through Interaction with SIRPα
Authors: Alexandre P.A. Theocharides, Liqing Jin, Po-Yan Cheng, Armando G. Poeppl, Tatiana K. Prasolava, Mark D. Minden, John E. Dick, Jayne S. Danska, Jean C.Y. Wang
Journal: Blood (2010)
T-Cell Abnormalities in Patients with Myelodysplastic Syndromes: Improved Immunological Functions in Patients Treated with Recombinant Erythropoietin.
Authors: Sara Prutchi-Sagiv, Nataliya Golishevski, Odelia Katz, Howard S. Oster, Elizabeth Naparstek, Michael Hoffman, Drorit Neumann, Moshe Mittelman
Journal: Blood (2006)
Trends in survival by race for stomach cancer patients from the U.S. SEER cancer registry.
Authors: L. Chu, L. Wang, M. Shing, W. Dong
Journal: Journal of Clinical Oncology (2011)

1548 Background: Incidence and mortality rates for stomach cancer (SC) in the US have decreased steadily for years, but trends in survival are limited. The objective of this study was to describe median overall survival (OS) trends in US SC patients (pts) by race/ethnicity and tumor characteristics. Methods: SC pts diagnosed between 1978 and 2007 were identified in the Surveillance, Epidemiology, and End Results (SEER). SC was classified by tumor characteristics: tumor stage, anatomic site and sex. Frequency distribution and median OS (crude, unadjusted) were examined by time period (1978-1987, 1988-1997, 1998-2007) and race/ethnicity. Results: The median OS (months) by time period and race/ethnicity are presented in the table. Survival has increased modestly in the past 30 years, with Asians having the largest improvement. Asians have the longest median OS, followed by whites and blacks. Across all race/ethnicities, median OS in advanced stage pts has remained poor. Conclusions: Although survival has increased slightly over the last 30 years, prognosis for advanced stage SC remains particularly poor. In the U.S. SEER registry, Asian pts had longer median OS and greater improvement in survival over time compared to other ethnicities. Stomach cancer median OS* (months) (95% CI) 1978-1987 N=19,641 1988-1997 N=25,905 1998-2007 N=49,723 White 8 (7, 8) 8 (8, 9) 9 (NE, NE) Median age (yrs) 71 72 71 Anatomic site Cardia 8 (8, 9) 9 (9, 10) 10 (10, 11) Noncardia 7 (7, 8) 8 (NE, NE) 8 (8, 9) Tumor stage Localized 38 (34, 43) 39 (36, 42) 36 (33, 38) Regional 12 (12, 13) 14 (13, 14) 16 (15, 16) Distant 4 (NE, NE) 4 (NE, NE) 4 (NE, NE) Black 8 (7, 9) 8 (8, 9) 8 (8, 9) Median age (yrs) 67 69 69 Anatomic site Cardia 6 (5, 7) 6 (5, 8) 8 (7, 9) Noncardia 8 (7, 9) 9 (8, 9) 9 (8, 9) Tumor stage Localized 32 (24, 44) 39 (32, 49) 33 (28, 41) Regional 13 (11, 14) 14 (13, 17) 14 (13, 15) Distant 4 (3, 4) 3 (3, 4) 4 (3, 4) Asian 11 (10, 12) 13 (12, 14) 15 (14, 16) Median age (yrs) 69 70 71 Anatomic site Cardia 9 (5, 12) 11 (9, 12) 13 (11, 15) Noncardia 12 (10, 13) 13 (12, 14) 15 (14, 16) Tumor stage Localized 103 (78, 124) 115 (105, 132) 89 (78, 101) Regional 17 (15, 19) 18 (17, 19) 23 (21, 24) Distant 5 (4, 5) 4 (3, 4) 5 (NE, NE) * Crude, unadjusted. Abbreviation: NE, not estimable.
TMOD-05. REGIONAL ASTROCYTE HETEROGENEITY INFLUENCES EVOLUTION OF LOW-GRADE GLIOMA DURING MALIGNANT PROGRESSION
Authors: David Irvin, Mark Vitucci, Robert McNeill, Ryan Bash, C. Ryan Miller
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) has a dismal median survival of around 15 months. Primary and secondary GBM likely evolve from low-grade precursors, albeit via distinct genetic and kinetic mechanisms. Primary GBM is composed of four transcriptome subtypes with distinct mutations and transcriptomes reminiscent of particular brain cells, suggesting that mutations and cellular origin contribute to GBM heterogeneity. However, the effects of regional heterogeneity among putative cells of origin on GBM pathogenesis remain elusive. We used genetic lineage tracing and fate mapping in conditional, inducible mice to show that inactivating Rb (T) and Pten (P) combined with activating Kras (R) (TRP) mutations transformed two subpopulations of mouse astrocytes expressing Gfap or Glast. While a large, broadly-distributed population of astrocytes were Gfap+ (~50%), Glast astrocytes were less abundant (8-38%) and regionally variable. Transformation of each subpopulation by the same oncogenic TRP mutations produced tumors with distinct growth kinetics. Gfap astrocyte transformation induced low-grade tumors with uniformly rapid growth, clonal expansion (Ki-67 labeling), and progression to lethal, GBM. In contrast, Glast astrocyte transformation induced regionally variable tumors with indolent growth, protracted clonal expansion, and progression to anaplastic, non-GBM gliomas. In addition to growth kinetics, we found that regional astrocyte heterogeneity influenced the genomic profiles of both low- and high-grade tumors. Cortical, low-grade Gfap-TRP tumor transcriptomes differed from those in the olfactory bulb, and brain region correlated with transcriptome subtype and copy number alterations (CNA) in high-grade tumors. High-grade tumors also acquired CNA and missense mutations (Trp53) and their transcriptomes evolved during the course of malignant progression. We are currently exploring whether distinct molecular mechanisms develop in tumors derived from transformed Glast astrocytes. These findings suggest that brain region influences both the genomics of glioma evolution as well as growth kinetics. Thus, Gfap- and Glast-TRP may represent tractable models of primary and secondary GBM, respectively.
ATIM-20. A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE ERC-1671 (GLIOVAC) VACCINE IN COMBINATION WITH BEVACIZUMAB (BEV) IN RECURRENT GBM PATIENTS: SAFETY LEAD-IN ANALYSIS
Authors: Daniela Bota, Jose Carrillo, Xiao-Tang Kong, Dan Fu, Jinah Chung, Chrystel Pretto, Ankie Strik, Virgil Schijns, Apostolos Stathopoulos
Journal: Neuro-Oncology (2016)

Recurrence of malignant gliomas following surgery, radiation therapy and adjuvant chemotherapy is nearly universal. The only approved second-line treatment for malignant gliomas is Bevacizumab (Avastin), with estimated 6-month progression-free survival rates of less than 40%. Ultimately, all the GBM patients relapse on Bevacizumab, and no other effective therapies are available. ERC-1671 aims at stimulating the patients' immune system by including patient's glioblastoma tumor as lysates and cells as well as heterologous component generated from three different GBM donors. The NCT01903330 study opened in 2014, and was mandated by the FDA to start with a single –institution, safety lead-in phase before extending to multiple centers. Eligible patients were over 18 years of age, had histologically confirmed WHO grade IV malignant glioma and have failed the treatment with radiation and temozolomide. Primary end points are toxicity and 6-month progression-free survival (PFS) while secondary endpoints are safety and overall survival (OS). Data reported as May 1st, 2016 - we have enrolled eight patients - which completed the safety lead-in analysis. Median age was 57, with 2/8 female patients. The average KPS was 80 (70–100). Four patients have stable disease, and their treatment group is not known to the investigator. Four patients had disease progression (at which point the protocol allows for un-blinding), two in the active treatment group and two in the control (BEV) group. No grade 4 or 5 AEs occurred. The grade 3 AEs were intracranial hemorrhage (in the control group), muscle weakness/myalgia (in the control group) and headaches (all three group). The most common AE was headache. Based on this safety report, we have now amended the study to allow multi-site enrollment. Updated results will be presented at the SNO meeting.
195P Irinotecan plus cetuximab (Cmab) versus irinotecan plus panitumumab (Pmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) as third- line in daily practice
Authors: N. Sugimoto, A. Hasegawa, F. Fujisawa, T. Yoshinami, T. Yagi, F. Imamura
Journal: Annals of Oncology (2016)
High Survival Rate in Adult Burkitt’s Lymphoma/Leukemia and Diffuse Large B-Cell Lymphoma with Mediastinal Involvement.
Authors: Dieter Hoelzer, Wolfgang Hiddemann, Anita Baumann, Hartmut Döhner, Ulrich Dührsen, Rainer Fietkau, Martin-Leo Hansmann, Andreas Hüttmann, Sebastian Irmer, Stephan Kaun, Michael Kneba, Albrecht Reichle, Mathias Schmid, Ingo Schmidt-Wolf, Eckard Thiel, Jan Walewski, Nicola Gökbuget
Journal: Blood (2007)
Clinical utility of gene-expression profiling for tumor site origin.
Authors: H. R. Gutierrez, J. C. Hornberger, G. R. Varadhachary, R. J. Hornberger, W. D. Henner, S. Becker, M. Walker, M. Amin, J. S. Nystrom
Journal: Journal of Clinical Oncology (2011)

e21093
Differential Prevalence of Anti-Heparin-Platelet Factor 4 Antibodies In Elderly Patients with Acute Hip Fracture Undergoing Orthopaedic Surgery and Anticoagulated with Unfractionated Heparin and Enoxaparin
Authors: Christopher Song, Josephine Cunanan, Hussein Kahn, Debra Hoppensteadt, Jawed Fareed
Journal: Blood (2010)
134P Safety and efficacy of eribulin and trastuzumab in anti-HER2 therapy pretreated patients with HER2-positive metastatic breast cancer: A Japanese multicenter phase 2 study (SBP-04 study)
Authors: T. Shien, M. Ikeda, S. Ohtani, F. Hara, M. Takahashi, H. Tuji, S. Yoshitomi, K. Matsuoka, Y. Ogasawara, N. Taira, H. Doihara, S. Ohsumi
Journal: Annals of Oncology (2016)